Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma
Tumor organoids, an in-vitro three-dimensional model, possess high potential for investigating tumor biology and treatment response and have been demonstrated more appropriate for drug assessment than two-dimensional cultures. Herein, we described two cases of invasive high-grade urothelial carcinom...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1424677/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284873580806144 |
|---|---|
| author | Xun Liu Xuebing Han Shuqing Wei Changwen Zhang |
| author_facet | Xun Liu Xuebing Han Shuqing Wei Changwen Zhang |
| author_sort | Xun Liu |
| collection | DOAJ |
| description | Tumor organoids, an in-vitro three-dimensional model, possess high potential for investigating tumor biology and treatment response and have been demonstrated more appropriate for drug assessment than two-dimensional cultures. Herein, we described two cases of invasive high-grade urothelial carcinoma who underwent radical cystectomy successfully following use of patient-derived organoids (PDOs) for drug screening to inform therapeutic decisions. In these two cases, the PDOs cultured by biopsy tissues were both sensitive to the combination of gemcitabine and cisplatin. After neoadjuvant chemotherapy (NAC) with gemcitabine and cisplatin, the patients responded well, and radical cystectomy was performed successfully. No recurrence or metastasis was observed within 6 months after surgery. This small case series suggests that the patient-derived urothelial carcinoma organoids contribute to optimizing NAC options to guide personalized treatment and improve the survival outcomes. |
| format | Article |
| id | doaj-art-3fe2db0a8dfd4ac995c28d43d7f665f4 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-3fe2db0a8dfd4ac995c28d43d7f665f42025-08-20T01:47:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14246771424677Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinomaXun Liu0Xuebing Han1Shuqing Wei2Changwen Zhang3Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, ChinaDepartment of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaDepartment of General Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, ChinaTumor organoids, an in-vitro three-dimensional model, possess high potential for investigating tumor biology and treatment response and have been demonstrated more appropriate for drug assessment than two-dimensional cultures. Herein, we described two cases of invasive high-grade urothelial carcinoma who underwent radical cystectomy successfully following use of patient-derived organoids (PDOs) for drug screening to inform therapeutic decisions. In these two cases, the PDOs cultured by biopsy tissues were both sensitive to the combination of gemcitabine and cisplatin. After neoadjuvant chemotherapy (NAC) with gemcitabine and cisplatin, the patients responded well, and radical cystectomy was performed successfully. No recurrence or metastasis was observed within 6 months after surgery. This small case series suggests that the patient-derived urothelial carcinoma organoids contribute to optimizing NAC options to guide personalized treatment and improve the survival outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2024.1424677/fullurothelial carcinomapatient-derived organoidsneoadjuvant chemotherapytreatment responsedrug sensitivity testing |
| spellingShingle | Xun Liu Xuebing Han Shuqing Wei Changwen Zhang Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma Frontiers in Oncology urothelial carcinoma patient-derived organoids neoadjuvant chemotherapy treatment response drug sensitivity testing |
| title | Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma |
| title_full | Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma |
| title_fullStr | Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma |
| title_full_unstemmed | Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma |
| title_short | Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma |
| title_sort | case report patient derived organoids promoting personalized treatment in invasive urothelial carcinoma |
| topic | urothelial carcinoma patient-derived organoids neoadjuvant chemotherapy treatment response drug sensitivity testing |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1424677/full |
| work_keys_str_mv | AT xunliu casereportpatientderivedorganoidspromotingpersonalizedtreatmentininvasiveurothelialcarcinoma AT xuebinghan casereportpatientderivedorganoidspromotingpersonalizedtreatmentininvasiveurothelialcarcinoma AT shuqingwei casereportpatientderivedorganoidspromotingpersonalizedtreatmentininvasiveurothelialcarcinoma AT changwenzhang casereportpatientderivedorganoidspromotingpersonalizedtreatmentininvasiveurothelialcarcinoma |